New salidroside-furoxan hybrids as potential agents inhibit triple-negative breast cancer

  • Bioorg Med Chem Lett. 2026 Jul:136:130627. doi: 10.1016/j.bmcl.2026.130627.
Bing Zhang  1 ,  Yongqing Zhang  1 ,  Siqi Zhang  1 ,  Na Li  2 ,  Li Chen  3
Affiliations
  • 1. State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.
  • 2. State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China. Electronic address: [email protected].
  • 3. State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China. Electronic address: [email protected].
Abstract

Salidroside (SAL) is a natural glycoside compound with various biological activities. Recent studies have shown that SAL exhibits certain therapeutic effects on Triple-Negative Breast Cancer (TNBC). To enhance the anti-TNBC activity, 15 SAL-furoxan hybrids were designed and synthesized. The anti-proliferative activities of all target compounds against four tumor cell lines (MDA-MB-231, MCF-7, BGC-823, and A549) and a normal human cell line (MCF-10A) were evaluated using the MTT assay. A12 demonstrated the most potent inhibitory activity on MDA-MB-231 cells (IC₅₀ = 14 nM), and lower toxicity compared to DOX (SI = IC50(MCF-10A)/IC50(MDA-MB-231): 129.57 vs 1.01). Further research indicated that the anti-tumor mechanism of A12 involves the high amount of NO released in MDA-MB-231 cells and thereby induction of cells Apoptosis.

Keywords
Hybrid; Phenylsulfonyl furoxan; Salidroside; TNBC.
Products